Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
作者信息
Stuver Robert, Shah Gunjan L, Korde Neha S, Roeker Lindsey E, Mato Anthony R, Batlevi Connie L, Chung David J, Doddi Sital, Falchi Lorenzo, Gyurkocza Boglarka, Hamilton Audrey, Lin Ya-Hui, Jakubowski Ann A, Joffe Erel, Landau Heather L, Lin Richard J, Mailankody Sham, Palomba M Lia, Park Jae H, Perales Miguel-Angel, Ponce Doris M, Ramanathan Lakshmi V, Salles Gilles A, Scordo Michael, Seo Susan K, Shah Urvi A, Stein Eytan M, Straus David, Usmani Saad Z, Young James W, Zelenetz Andrew D, Noy Ariela, Vardhana Santosha A
机构信息
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Cancer Cell. 2022 Jun 13;40(6):590-591. doi: 10.1016/j.ccell.2022.05.007. Epub 2022 May 16.
Abstract
摘要
相似文献
1
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.AZD7442（替沙格韦单抗-西加韦单抗）对血液系统恶性肿瘤患者中奥密克戎SARS-CoV-2的活性。
Cancer Cell. 2022 Jun 13;40(6):590-591. doi: 10.1016/j.ccell.2022.05.007. Epub 2022 May 16.
2
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.半衰期延长的严重急性呼吸综合征冠状病毒 2 中和单克隆抗体 AZD7442（替沙格韦单抗-西加韦单抗）在健康成年人中的安全性、耐受性和药代动力学。
J Infect Dis. 2023 May 12;227(10):1153-1163. doi: 10.1093/infdis/jiad014.
3
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients.奥密克戎突破感染的预测因素，在血液恶性肿瘤患者接受 AZD7442（替沙吉韦单抗-西加韦单抗）用于暴露前预防后。
Haematologica. 2023 Nov 1;108(11):3058-3067. doi: 10.3324/haematol.2023.283015.
4
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.加速大流行期间的治疗药物研发：长效抗体联合制剂 AZD7442（替沙格韦单抗/西加韦单抗）在 COVID-19 预防和治疗中的群体药代动力学。
Antimicrob Agents Chemother. 2024 May 2;68(5):e0158723. doi: 10.1128/aac.01587-23. Epub 2024 Mar 27.
5
Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy.替沙格韦单抗/西加韦单抗（AZD7442/埃武尤单抗）预防正在接受积极化疗的血液恶性肿瘤患者的 COVID19。
Ann Hematol. 2024 Jul;103(7):2533-2539. doi: 10.1007/s00277-024-05769-x. Epub 2024 Apr 28.
6
Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.SARS-CoV-2 奥密克戎亚变种在 COVID-19 免疫功能低下患者中的基因和表型分析，这些患者在接受 tixagevimab-cilgavimab 预防治疗后。
J Clin Virol. 2023 Mar;160:105382. doi: 10.1016/j.jcv.2023.105382. Epub 2023 Jan 26.
7
Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.系统评价和荟萃分析：替沙格韦单抗/西加韦单抗用于预防免疫功能低下患者 COVID-19 的临床效果。
Br J Haematol. 2023 Jun;201(5):813-823. doi: 10.1111/bjh.18782. Epub 2023 Apr 3.
8
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.奥密克戎变异株流行期间替沙格韦单抗/西加韦单抗和静注 COVID-19 人免疫球蛋白（COVIDIg）单克隆抗体治疗 COVID-19 的真实世界临床疗效。
Front Immunol. 2023 Oct 20;14:1259725. doi: 10.3389/fimmu.2023.1259725. eCollection 2023.
9
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.接受替沙格韦单抗/西加韦单抗被动预先暴露免疫的血液系统恶性肿瘤合并 COVID-19 患者：EPICOVIDEHA 登记研究的配对分析。
J Hematol Oncol. 2023 Apr 1;16(1):32. doi: 10.1186/s13045-023-01423-7.
10
A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment.对西加韦单抗和替沙格韦单抗单克隆抗体鸡尾酒（Evusheld）用于 COVID-19 预防和治疗的批判性分析。
Viruses. 2022 Sep 9;14(9):1999. doi: 10.3390/v14091999.
引用本文的文献
1
SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era.奥密克戎时代替沙格韦单抗-西加韦单抗用于血液系统、免疫功能低下患者的SARS-CoV-2暴露前预防
Eur J Haematol. 2025 Apr;114(4):690-699. doi: 10.1111/ejh.14377. Epub 2025 Jan 6.
2
Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study.替沙格韦单抗-西加韦单抗用于 COVID-19 免疫功能低下 20 至 <40 千克儿童和青少年暴露前预防的免疫原性和安全性：一项前瞻性、开放标签、初步研究。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2428011. doi: 10.1080/21645515.2024.2428011. Epub 2024 Nov 22.
3
Efficacy of Combination of Antiviral Therapy With Neutralizing Monoclonal Antibodies for Recurrent Persistent SARS-CoV-2 Pneumonia in Patients With Lymphoma.抗病毒治疗联合中和单克隆抗体治疗淋巴瘤患者复发性持续性 SARS-CoV-2 肺炎的疗效。
Biomed Res Int. 2024 Aug 6;2024:8182887. doi: 10.1155/2024/8182887. eCollection 2024.
4
Patients with multiple myeloma infected with COVID-19 during autologous stem cell transplantation.在自体干细胞移植期间感染新冠病毒的多发性骨髓瘤患者。
Infect Agent Cancer. 2024 Aug 12;19(1):38. doi: 10.1186/s13027-024-00603-5.
5
Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives.骨髓纤维化的流行病学及疾病特征：意大利与全球视角的比较分析
Front Oncol. 2024 Jul 24;14:1382872. doi: 10.3389/fonc.2024.1382872. eCollection 2024.
6
Prospects of Innovative Therapeutics in Combating the COVID-19 Pandemic.创新疗法抗击新冠疫情的前景
Mol Biotechnol. 2025 Jul;67(7):2598-2606. doi: 10.1007/s12033-024-01240-4. Epub 2024 Aug 1.
7
Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study.替沙格韦单抗/西加韦单抗在免疫功能低下个体中用于新冠病毒暴露前预防的真实世界应用：来自章鱼研究的数据
Vaccines (Basel). 2024 Jul 17;12(7):784. doi: 10.3390/vaccines12070784.
8
HPLC-MS/MS-based quantification of human monoclonal antibodies targeting SARS-CoV-2 in the presence of endogenous SARS-CoV-2 antibodies in human serum.基于 HPLC-MS/MS 的人源单克隆抗体定量分析方法，用于检测人血清中针对 SARS-CoV-2 的内源性抗体。
Anal Bioanal Chem. 2024 Aug;416(19):4383-4396. doi: 10.1007/s00216-024-05375-w. Epub 2024 Jun 21.
9
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.管理和治疗血液系统恶性肿瘤患者的 COVID-19：叙述性综述和专家观点。
Clin Exp Med. 2024 Jun 4;24(1):119. doi: 10.1007/s10238-024-01381-5.
10
Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy.替沙格韦单抗/西加韦单抗（AZD7442/埃武尤单抗）预防正在接受积极化疗的血液恶性肿瘤患者的 COVID19。
Ann Hematol. 2024 Jul;103(7):2533-2539. doi: 10.1007/s00277-024-05769-x. Epub 2024 Apr 28.
本文引用的文献
1
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.肌肉注射 AZD7442（替沙格韦单抗-西加韦单抗）预防新冠病毒感染。
N Engl J Med. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. Epub 2022 Apr 20.
2
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.接受单克隆抗体治疗的患者对 SARS-CoV-2 奥密克戎亚谱系 BA.1 和 BA.2 的血清中和作用。
Nat Med. 2022 Jun;28(6):1297-1302. doi: 10.1038/s41591-022-01792-5. Epub 2022 Mar 23.
3
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.抗病毒药物对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚型BA.2的疗效
N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.
4
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.SARS-CoV-2 奥密克戎亚谱系的抗体逃逸特性。
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
5
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.一种传染性 SARS-CoV-2 B.1.1.529 奥密克戎病毒能够逃避治疗性单克隆抗体的中和作用。
Nat Med. 2022 Mar;28(3):490-495. doi: 10.1038/s41591-021-01678-y. Epub 2022 Jan 19.
6
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy.造血细胞移植和嵌合抗原受体 T 细胞治疗后对 SARS-CoV-2 疫苗的体液反应的预测因素。
Blood Cancer Discov. 2021 Sep 13;2(6):577-585. doi: 10.1158/2643-3230.BCD-21-0142. eCollection 2021 Nov.
7
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.血液恶性肿瘤患者中疾病和治疗特异性对 COVID-19 疫苗接种后体液免疫应答的影响。
Blood Cancer Discov. 2021 Sep 13;2(6):568-576. doi: 10.1158/2643-3230.BCD-21-0139. eCollection 2021 Nov.
8
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.接种疫苗的血液系统恶性肿瘤成年患者中的 COVID-19：来自 EPICOVIDEHA 的初步结果。
Blood. 2022 Mar 10;139(10):1588-1592. doi: 10.1182/blood.2021014124.
9
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.血液系统恶性肿瘤合并 COVID-19 患者的结局：对 3377 例患者的系统评价和荟萃分析。
Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824.
Zotero 插件